Weekly Glance for February 11th

What's new in optometry, week by week.

This week is sponsored by


An approved treatment for myopia is on the horizon.

The FDA just accepted the investigational new drug application for MicroPine.

Explain that entire last sentence.
An investigational new drug application is when a pharmaceutical company is given permission to test their experimental drug on real humans and ship it across state lines to test said drug at multiple different centers.

Got it. What is MicroPine?
MicroPine is a formulation of low dose atropine given to slow myopia progression. This builds off of the work of the ATOM1 and ATOM2 studies. Now that the company has the go ahead from the FDA, they will begin enrolling kids between the ages of 5-12 in their CHAPERONE clinical trial.

Anything else cool about this?
Yes, MicroPine is unique because it delivers atropine in "microdrops". Microdrops are a smaller amount of an eye drop that delivers the same therapeutic effect. Typical eye drop bottles dispense roughly three times the amount that an eye can hold. Microdrops dispense the exact amount the eye can hold and Eyenovia has the proprietary technology. See their eye-dropper-of-the-future here.

Why could this be a big deal?
Two reasons.
1. The microdrops technology could be a hit given that smaller drops limit surface toxicity and Eyenovia is trying to apply this to all areas of therapeutics (glaucoma, allergy, etc). 
2. This could be the first FDA approved atropine therapy for myopia control.



Are daily contacts healthier than reusable contacts?

Still yes.
A new study was just published in Cornea examining daily vs. reusable contacts and their effect on the ocular surface.

Tell me about the study.
The authors divided patients into three groups and had them wear one of three different type of contacts:
1. Daily disposable hydrogel contacts (22 people).
2. Daily disposable silicone hydrogel contacts (25 people).
3. Reusable silicone hydrogel contacts (24 people).

What did they measure?
They performed tear function tests and measured proinflammatory cytokine levels before contact lens wear and at 1 and 3 months after using contacts.

What did they find?
1. Less proinflammatory cytokines in the tears of daily contact lens wearers as compared to reusable lens wearers. The lowest level was in the daily hydrogel wearers.
2.  Compared to the pre-contact lens wearing baseline testing, there was an increase in proinflammatory cytokines in all groups.

The take home:
Per the authors, "daily disposable CLs can be considered to cause less damage to the ocular surface and less increase in proinflammatory cytokine levels."



Patients are not the most truthful bunch of people.

A new survey found that over 60% of patients have admitted to withholding information about their medical health from their provider. (via)

Texas OD's.

The legislative battle made the Texas Tribune news last week.


Johnson & Johnson said they will give the list price of their prescription drugs in their commercials. They would be the first drug company to do this.
This is sponsored content by Vision Expo!

Looking for a quick getaway in March? I've got the place!

Come to Vision Expo East with me!
This conference is packed with great education, thousands of frame brands, cutting-edge technology, and tons of networking opportunities. In just a few short days you can knock out a lot of CE, meet up with old friends, make new ones (hi!) and see the sights of NYC. Register for free here!

This week, I want to introduce Rich Zimbalist. He is an optometrist in Missouri that took his passion for web design and built a company called Ignite Medical. When he isn't seeing patients during the day, he is working on getting his clients on the first page of Google. Great job, Rich!
Hope you have a great week! See you next Monday!
Jackie Garlich
Editor & Founder // 20/20 Glance

Enjoy this email? Tell your friends to sign up here!
Copyright © 2019 2020glance, All rights reserved.

Email Me // About // Update Profile // Unsubscribe